Current Issue

View Larger Image

Past Issues Adlink Subscription Visit Our Publisher

ADVERTISEMENT



Top Keywords




GENpoll: Jun 15, 2009

Making Cancer Treatments Patient-Specific

How long do you think it will take for a cancer vaccine to reach the U.S. market?

Within the next year or so
 
  11.2%
At least another five years
 
  65.2%
Never
 
  16.1%
Undecided
 
  7.5%

Suggest a Poll
« More Polls » « View Results »
Given the success of Dendreon’s and Biovest’s cancer vaccines in late-stage trials, some believe that the promise of personalized therapy in cancer is around the corner. Yet we’re also seeing other similar vaccines fail in Phase III studies. Manufacturing issues and the high cost of producing such therapies are some of the barriers that have been holding the field back. What’s your prediction for the future of personalized cancer medicine in the U.S.?

Related content

New Products

Subscription center

GEN MAGAZINE

Genetic Engineering & Biotechnology News (GEN) has retained its position as the most widely read biotechnology publication around the globe since its launch in 1981. Published 21 times a year and with additional exclusive editorial content online, GEN's unique news and technology focus includes the entire bioproduct life cycle from early-stage R&D, to applied research including omics, biomarkers, as well as diagnostics, to bioprocessing and commercialization.

Subscribe
e-NEWSLETTERS

Add GEN to your Inbox! Subscribe today to our complimentary e-newsletters and stay abreast of the latest biotech news and trends. Click the magnifying glass icon next to a newsletter title to view a sample.

 

All fields are required

Email
Confirm Email
First Name
Last Name
Organization
E-Alert Format
 
 
  Sign Up

ADVERTISEMENT

ADVERTISEMENT

ADVERTISEMENT

GENpoll

Funding Early-Stage Companies

How much do you think newly established funds will succeed in helping startups?

Suggest a Poll